Peng Yihang, Wang Han, Fang Qin, Xie Liling, Shu Lingzhi, Sun Wenjing, Liu Qin
First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Joint Surgery, Chongqing Medical University, Chongqing, China.
J Manag Care Spec Pharm. 2020 Apr;26(4):550-561. doi: 10.18553/jmcp.2020.26.4.550.
Medication adherence is frequently suboptimal in adults with chronic diseases, resulting in negative consequences. Traditional interventions to improve adherence are complex and not widely effective. Mobile applications may be a scalable means to support medication adherence.
To investigate the effect of mobile apps on medication adherence in adults with chronic diseases.
MEDLINE, EMBASE, CINAHL Plus, Cochrane Central Register of Controlled Trials, and Web of Science were searched for randomized controlled trials evaluating the effectiveness of any mobile application (app) intervention directed at patients with chronic disease to improve medication adherence in comparison with usual care. A random-effects model was used to pool the outcome data. Risk of bias and quality of study were assessed per Cochrane guidelines.
Fourteen studies were included in this systematic review involving 1,785 participants, 940 of whom were randomized to a mobile app intervention group and 845 to the usual care group. The meta-analysis showed that the use of mobile apps was associated with a significant improvement in patient adherence to medication (Cohen's d = 0.40, 95% CI = 0.27-0.52; < 0.001), with a low quality of GRADE evidence. There was no evidence of publication bias (Egger's test; = 0.81) or substantial heterogeneity (I = 29%). In the sensitivity analysis, our findings remained robust to change in inclusion criteria based on study quality (Cohen's d = 0.43, 95% CI = 0.33-0.54; < 0.001). The included apps incorporated 9 features, sorted from high to low based on relative weights (RW): documentation (RW = 0.254), medication reminder (RW = 0.204), data sharing (RW = 0.148), feedback message (RW = 0.104), clinical decision support (RW = 0.097), education (RW = 0.081), customization (RW = 0.049), data statistics (RW = 0.041), and appointment reminder (RW = 0.041). In the subgroup analysis, the effect was not sensitive to study characteristics or app features (0.37 ≤ ≤ 0.95). App acceptability was reported by participants in the intervention group in 8 studies: 144 of 156 participants (91.7%) were satisfied with all aspects of the apps.
Compared with conventional care, mobile apps are effective interventions to help improve medication adherence in adults with chronic diseases. Although promising, these results should be interpreted with caution given the low level of evidence and short intervention duration. Future research will not only need to identify ideal app features and the costs to providers but also need to improve the apps to make them user friendly, secure, and effective based on patient-centered theory.
Funding for this study was provided by Chongqing Science and Technology Bureau (No. cstc2017shmsA130115). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have no conflicts of interest to disclose.
慢性病成年患者的药物依从性常常欠佳,会产生不良后果。传统的提高依从性的干预措施复杂且效果并不广泛。移动应用程序可能是一种可扩展的支持药物依从性的手段。
探讨移动应用程序对慢性病成年患者药物依从性的影响。
检索MEDLINE、EMBASE、CINAHL Plus、Cochrane对照试验中心注册库和Web of Science,查找评估任何针对慢性病患者的移动应用程序(应用)干预措施与常规护理相比改善药物依从性有效性的随机对照试验。采用随机效应模型汇总结局数据。根据Cochrane指南评估偏倚风险和研究质量。
本系统评价纳入14项研究,涉及1785名参与者,其中940名被随机分配到移动应用程序干预组,845名被分配到常规护理组。荟萃分析表明,使用移动应用程序与患者药物依从性显著改善相关(Cohen's d = 0.40,95%CI = 0.27 - 0.52;P < 0.001),GRADE证据质量低。没有证据表明存在发表偏倚(Egger检验;P = 0.81)或实质性异质性(I² = 29%)。在敏感性分析中,基于研究质量改变纳入标准时,我们的研究结果仍然稳健(Cohen's d = 0.43,95%CI = 0.33 - 0.54;P < 0.001)。纳入的应用程序包含9个功能,根据相对权重(RW)从高到低排序:记录(RW = 0.254)、用药提醒(RW = 0.204)、数据共享(RW = 0.148)、反馈消息(RW = 0.104)、临床决策支持(RW = 0.097)、教育(RW = 0.081)、定制(RW = 0.049)、数据统计(RW = 0.041)和预约提醒(RW = 0.041)。在亚组分析中,效应对研究特征或应用功能不敏感(0.37 ≤ I² ≤ 0.95)。8项研究中的干预组参与者报告了应用程序的可接受性:156名参与者中的144名(91.7%)对应用程序的各个方面感到满意。
与传统护理相比,移动应用程序是帮助改善慢性病成年患者药物依从性的有效干预措施。尽管前景广阔,但鉴于证据水平低和干预持续时间短,这些结果应谨慎解释。未来的研究不仅需要确定理想的应用程序功能和对提供者的成本,还需要根据以患者为中心的理论改进应用程序,使其用户友好、安全且有效。
本研究由重庆市科学技术局资助(编号cstc2017shmsA130115)。资助者在研究设计、数据收集和分析、出版决策或稿件准备过程中没有参与。作者没有利益冲突需要披露。